The regulator cleared Tecartus (brexucabtagene autoleucel) for the new indication after a swift review that focused on the ZUMA-3 trial, which showed that 65% of patients treated with the CAR-T ...

Known as Tecartus in the US, this is the third CAR-T therapy to be recommended for approval in Europe and will be the first for MCL, an aggressive form of non-Hodgkin’s lymphoma (NHL).

CD19-directed autologous CAR T cell therapies such as Gilead's (NASDAQ:GILD) Yescarta and Tecartus, Bristol Myers' (BMY) Breyanzi, and Novartis (NYSE:NVS) (OTCPK:NVSEF) Kymriah are also included ...